Advances in beta-blockers in patients with heart failure and atrial fibrillation
Author:
Affiliation:

Department of Cardiology, First People’s Hospital, Kunming, Yunnan 650000, China)

Clc Number:

R541

  • Article
  • | |
  • Metrics
  • |
  • Reference [41]
  • | | | |
  • Comments
    Abstract:

    Clinical benefits of β-blockers in heart failure have been shown to vary in sinus rhythm and atrial fibrillation in recent years. However, there is no clear evidence on a large scale. This review mainly expounds the action mechanism of β-blockers for heart failure combined with atrial fibrillation and the main clinical research progress of different β-blockers for such diseases.

    Reference
    [1] LEONG-SIT P, TANG A.Atrial fibrillation and heart failure:a bad combination.Curr Opin Cardiol, 5,0(2):161-167.
    [2] BAHER A, MARROUCHE N F.Management of atrial fibrillation in patients with heart failure:time to implement ablation control.Curr Cardiol Rep, 9,1(2):10.
    [3] DE WITH R R, RIENSTRA M, CRIJNS H, et al.Determinants of sinus rhythm maintenance in patients with early-persistent atrial fibrillation and heart failure.Clin Res Cardiol, 0,9(6):787-789.
    [4] YANCY C W, JESSUP M, BOZKURT B, et al.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol, 3,2(16):e147-e239.
    [5] PICCINI J P, ALLEN L A.Heart failure complicated by atrial fibrillation:don't bury the beta-blockers just yet.JACC Heart Fail, 7,5(2):107-109.
    [6] ABBASI M H, MAAN A, HEIST E K.The care of patients with atrial fibrillation and heart failure.Crit Pathw Cardiol, 1,0(2):93-99.
    [7] KOTECHA D, PICCINI J P.Atrial fibrillation in heart failure:what should we do.Eur Heart J, 5,6(46):3250-3257.
    [8] ARIYARATNAM J P, LAU D H, SANDERS P, et al.Atrial fibrillation and heart failure:epidemiology, pathophysiology, prognosis, and management.Card Electrophysiol Clin, 1,3(1):47-62.
    [9] ROSA G M, MELIOTA G, BRUNELLI C A.Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients.Expert Opin Drug Metab Toxicol, 7,3(4):473-481.
    [10] LONG D, XIAO Y, DONG B, et al.Being cast into the shade of β blockers for concomitant heart failure and atrial fibrillation.Int J Cardiol, 5,8:35.
    [11] RIENSTRA M, DAMMAN K, MULDER B, et al.Beta-blockers and outcome in heart failure and atrial fibrillation:a Meta-analysis.JACC Heart Fail, 3,1(1):21-28.
    [12] MAREEV Y, CLELAND J G.Should β-blockers be used in patients with heart failure and atrial fibrillation.Clin Ther, 5,7(10):2215-2224.
    [13] MAACK C, CREMERS B, FLESCH M, et al.Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium.Br J Pharmacol, 0,0(5):1131-1139.
    [14] MARROUCHE N F, BRACHMANN J.Catheter ablation for atrial fibrillation with heart failure.N Engl J Med, 8,9(5):492.
    [15] AHN M S, YOO B S, SON J W, et al.Beta-blocker therapy at discharge in patients with acute heart failure and atrial fibrillation.J Korean Med Sci, 0,5(33):e278.
    [16] CAMM A J, KIRCHHOF P, LIP G Y, et al.Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).Europace, 0,2(10):1360-1420.
    [17] PONIKOWSKI P, VOORS A A, ANKER S D, et al.2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur Heart J, 6,7(27):2129-2200.
    [18] SU V Y, CHANG Y S, HU Y W, et al.Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease.Medicine (Baltimore), 6,5(5):e2427.
    [19] KOTECHA D, HOLMES J, KRUM H, et al.Efficacy of β blockers in patients with heart failure plus atrial fibrillation:an individual-patient data Meta-analysis.Lancet, 4,4(9961):2235-2243.
    [20] XU T, HUANG Y, ZHOU H, et al.β-blockers and risk of all-cause mortality in patients with chronic heart failure and atrial fibrillation-a Meta-analysis.BMC Cardiovasc Disord, 9,9(1):135.
    [21] BRISTOW M R, RODEN R L, LOWES B D, et al.The role of third-generation beta-blocking agents in chronic heart failure.Clin Cardiol, 8,1(12 Suppl 1):I3-13.
    [22] KHAND A U, RANKIN A C, MARTIN W, et al.Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure.J Am Coll Cardiol, 3,2(11):1944-1951.
    [23] KISHIHARA J, NIWANO S, NIWANO H, et al.Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation.Cardiovasc Diagn Ther, 4,4(1):28-35.
    [24] KHAND A U, CHEW P G, DOUGLAS H, et al.The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.Cardiology, 5,0(3):153-158.
    [25] BRISTOW M R.Beta-adrenergic receptor blockade in chronic heart failure.Circulation, 0,1(5):558-569.
    [26] COHN J N, LEVINE T B, OLIVARI M T, et al.Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.N Engl J Med, 4,1(13):819-823.
    [27] ROSA G M, MELIOTA G, BRUNELLI C A.Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients.Expert Opin Drug Metab Toxicol, 7,3(4):473-481.
    [28] DE LIMA-SEOLIN B G, NEMEC-BAKK A, FORSYTH H, et al.Bucindolol modulates cardiac remodeling by attenuating oxidative stress in H9c2 cardiac cells exposed to norepinephrine.Oxid Med Cell Longev, 9,9:6325424.
    [29] ALEONG R G, SAUER W H, DAVIS G, et al.Prevention of atrial fibrillation by bucindolol is dependent on the beta 389 Arg/Gly adrenergic receptor polymorphism.JACC Heart Fail, 3,1(4):338-344.
    [30] O'CONNOR C M, FIUZAT M, CARSON P E, et al.Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms.PLoS One, 2,7(10):e44324.
    [31] PICCINI J P, ABRAHAM W T, DUFTON C, et al.Bucindolol for the maintenance of sinus rhythm in a genotype-defined HF population:the GENETIC-AF trial.JACC Heart Fail, 9,7(7):586-598.
    [32] SHAH P, METRA M.GENETIC-AF:digging deeper into genotype-phenotype and heart failure-atrial fibrillation interactions.JACC Heart Fail, 9,7(7):599-601.
    [33] ALKHATIB N, SWEITZER N K, LEE C S, et al.Ex ante economic evaluation of Arg389 genetically targeted treatment with bucindolol versus empirical treatment with carvedilol in NYHA Ⅲ/Ⅳ heart failure.Am J Cardiovasc Drugs, 1,1(2):205-217.
    [34] 申宇娟, 冯炎青, 边云飞.心房颤动的基因学研究进展.中国动脉硬化杂志, 7,5(8):856-860.
    [35] PRYSTOWSKY E N, PADANILAM B J, FOGEL R I.Treatment of atrial fibrillation.JAMA, 5,4(3):278-288.
    [36] 叶显华, 袁洪, 凌峰, 等.静脉应用地尔硫卓和美托洛尔治疗老年心功能衰竭伴心房颤动快速心室率的疗效和安全性比较.中国动脉硬化杂志, 7,5(3):224-226.
    [37] VINEREANU D, SPINAR J, PATHAK A, et al.Role of metoprolol succinate in the treatment of heart failure and atrial fibrillation:a systematic review.Am J Ther, 0,7(2):e183-e193.
    [38] YAMADA S, LO L W, CHEN S.Reply to letter to the editor:“A potential and lionhearted soldier for atrial fibrillation accompanied with heart failure:renal denervation”.Int J Cardiol, 7,3:282.
    [39] CARNAGARIN R, KIUCHI M G, GOH G, et al.Role of the sympathetic nervous system in cardiometabolic control:implications for targeted multiorgan neuromodulation approaches.J Hypertens, 1,9(8):1478-1489.
    [40] LONG D, XIAO Y, DONG B, et al.Being cast into the shade of β blockers for concomitant heart failure and atrial fibrillation.Int J Cardiol, 5,8:35.
    [41] YAMADA S, LO L W, CHOU Y H, et al.Renal denervation regulates the atrial arrhythmogenic substrates through reverse structural remodeling in heart failure rabbit model.Int J Cardiol, 7,5:105-113.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

DONG Xiaoping, MA Juan, DENG Ziwei, CHEN Xingyong. Advances in beta-blockers in patients with heart failure and atrial fibrillation[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2022,30(2):171-174.

Copy
Share
Article Metrics
  • Abstract:550
  • PDF: 655
  • HTML: 0
  • Cited by: 0
History
  • Received:January 19,2021
  • Revised:July 18,2021
  • Online: January 07,2022
Article QR Code